These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Choueiri TK; Raghavan D Nat Clin Pract Oncol; 2008 Aug; 5(8):444-54. PubMed ID: 18577983 [TBL] [Abstract][Full Text] [Related]
5. Current status of bladder cancer protocols in the EORTC Genito-Urinary Group. Denis L; Pavone-Macaluso M; De Pauw M Prog Clin Biol Res; 1984; 162B():429-39. PubMed ID: 6390450 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials in superficial and invasive bladder cancer. Smith PH Turk J Pediatr; 1984; 26(1-4):251-63. PubMed ID: 6443168 [No Abstract] [Full Text] [Related]
7. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600 [TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929 [TBL] [Abstract][Full Text] [Related]
9. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols. Prout GR; Kopp J Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644 [No Abstract] [Full Text] [Related]
11. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Merseburger AS; Kuczyk MA Curr Opin Urol; 2007 Sep; 17(5):358-62. PubMed ID: 17762631 [TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Herr HW Eur Urol; 2009 Apr; 55(4):920-1. PubMed ID: 18722043 [No Abstract] [Full Text] [Related]
13. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Witjes JA Eur Urol; 2009 Apr; 55(4):919. PubMed ID: 18722044 [No Abstract] [Full Text] [Related]
14. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058 [TBL] [Abstract][Full Text] [Related]
15. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study]. Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577 [TBL] [Abstract][Full Text] [Related]
17. Radical TUR and chemotherapy aiming at bladder preservation. Hall RR; Roberts JT; Marsh MM Prog Clin Biol Res; 1990; 353():163-8. PubMed ID: 2217414 [No Abstract] [Full Text] [Related]
18. [Combined therapy for patients with invasive bladder cancer]. Startsev VIu; Karelin MI Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212 [TBL] [Abstract][Full Text] [Related]
19. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. Colvett KT; Althausen AF; Bassil B; Heney NM; McGovern FV; Young HH; Kaufman DS; Zietman AL; Shipley WU J Surg Oncol; 1996 Nov; 63(3):201-8. PubMed ID: 8944067 [TBL] [Abstract][Full Text] [Related]
20. [Results of organ-preserving therapy for invasive bladder cancer]. Matveev BP; Figurin KM; Toktomushev AT Urologiia; 2002; (3):3-5. PubMed ID: 12180056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]